<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Gupta, Samir</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">BMS-986001 is Effective Treatment for HIV-1-Infected Subjects</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">16-17</style></pages><abstract><style  face="normal" font="default" size="100%">BMS-986001 is a novel nucleoside analog reverse-transcriptase inhibitor that, in higher doses, demonstrated comparable efficacy to tenofovir in treatment-naïve HIV-1-infected subjects. This article presents the results of this phase 2b randomized dose trial (active controlled, blinded to BMS-986001) with worldwide recruitment.</style></abstract><number><style face="normal" font="default" size="100%">28</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>